Weinberg's Pharma Omnium sells Biodim subsidiary
France-based Pharma Omnium International, a portfolio company of Weinberg Capital Partners (WCP), has sold its subsidiary Laboratoire Biodim to pharmaceutical business NuPharm, backed by Apax Partners.
Biodim was marketed based on EBITDA of €18m and valued at €130-140m, according to Unquote sister publication Mergermarket.
The vendor, Omnium, is a pharmaceutical company that markets mature drugs in various therapeutic classes. Founded in 2005 and based in Paris, the company provides nutraceutical, dermatological, and dermo-esthetic products.
The buyer of Biodim, NuPharm, has been owned by British sponsor Apax Partners since 2016. That year the GP bought Spanish business Invent Farma as well as Germany-headquartered Neuraxpharm, subsequently merging the two and rebranding the group as NuPharm.
NuPharm today consists of five speciality pharmaceutical companies: Neuraxpharm (Germany and Poland), Qualigen (Spain), FB Health (Italy), Laboratorios Lesvi (Spain), and Inke (Spain). NuPharm develops and markets branded, generic and nutraceutical pharmaceutical products, offering central nervous system treatment options to healthcare professionals and industry partners. The group is present in 50 countries.
Previous funding
Omnium was WCP's first investment in 2006. The newly established GP bought a 70% stake in Pharma Omnium, with the company's founders retaining the balance.
As part of the investment, the equity house provided a leveraged working capital facility to allow the company to acquire Biodim laboratories, a pharmaceutical company with a 2005 turnover of €43.7m. IKB provided A- and B-tranches of senior debt (60% of total investment value), while Babson Capital underwrote the mezzanine financing (20% of total investment value).
Omnium subsequently bolted-on Upharm laboratory in 2007 and Mutabilis in 2009.
Company
Biodim is a Paris-based laboratory that produces benzodiazepine drugs Temesta (Lorazepam) and Seresta (Oxazepam), among others. The business generates a turnover of around €32m
People
Weinberg Capital Partners – Benjamin Rousseau-Calisti (director).
NuPharm – Stephan Walz (CEO).
More on Exits
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Ares Management handed keys to two-thirds of UK sponsor’s portfolio
Lender provided GBP 500m for three of the GP's deals between 2016 and 2019, Debtwire reported
Actera Group explores strategic options for Celebi Ground Handling
Several investors placed bids for the company in 2022 but mismatch in pricing didn't lead to a deal
Main Capital’s Assessio to be sold to Pollen Street
Recruitment software company tripled in revenue under Main Capital’s ownership
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater